

RESEARCH

Open Access



Neuropsychological test performance of former American football players

Michael L. Alosco^{1*}, William B. Barr², Sarah J. Banks^{3,4}, Jennifer V. Wethe⁵, Justin B. Miller⁶, Surya Vamsi Pulukuri¹, Julia Culhane¹, Yorghos Tripodis^{7,8}, Charles H. Adler⁹, Laura J. Balcer^{2,10,11}, Charles Bernick^{6,12}, Megan L. Mariani¹, Robert C. Cantu¹, David W. Dodick⁵, Michael D. McClean¹³, Rhoda Au^{1,14,15,16,17}, Jesse Mez^{1,14}, Robert W. Turner II¹⁸, Joseph N. Palmisano¹⁹, Brett Martin¹⁹, Kaitlin Hartlage¹⁹, Jeffrey L. Cummings²⁰, Eric M. Reiman²¹, Martha E. Shenton^{22,23}, Robert A. Stern^{1,16,24} and for the DIAGNOSE CTE Research Project

Abstract

Background: Patterns of cognitive impairment in former American football players are uncertain because objective neuropsychological data are lacking. This study characterized the neuropsychological test performance of former college and professional football players.

Methods: One hundred seventy male former football players ($n=111$ professional, $n=59$ college; 45–74 years) completed a neuropsychological test battery. Raw scores were converted to T -scores using age, sex, and education-adjusted normative data. A T -score ≤ 35 defined impairment. A domain was impaired if 2+ scores fell in the impaired range except for the language and visuospatial domains due to the limited number of tests.

Results: Most football players had subjective cognitive concerns. On testing, rates of impairments were greatest for memory (21.2% two tests impaired), especially for recall of unstructured (44.7%) versus structured verbal stimuli (18.8%); 51.8% had one test impaired. 7.1% evidenced impaired executive functions; however, 20.6% had impaired Trail Making Test B. 12.1% evidenced impairments in the attention, visual scanning, and psychomotor speed domain with frequent impairments on Trail Making Test A (18.8%). Other common impairments were on measures of language (i.e., Multilingual Naming Test [21.2%], Animal Fluency [17.1%]) and working memory (Number Span Backward [14.7%]). Impairments on our tasks of visuospatial functions were infrequent.

Conclusions: In this sample of former football players (most of whom had subjective cognitive concerns), there were diffuse impairments on neuropsychological testing with verbal memory being the most frequently impaired domain.

Keywords: Alzheimer's disease, American football, Chronic traumatic encephalopathy, Cognitive function, Neuropsychology, Repetitive head impacts

Background

Repetitive head impacts (RHI) from American football have been associated with later-life cognitive symptoms [1–6] and chronic traumatic encephalopathy (CTE) [5, 7–9]. We use the term RHI herein to refer to environmental exposures to repetitive impacts, hits, or blows to the head. These impacts can result in symptomatic traumatic brain injuries (e.g., concussion) and/or less discrete cumulative effects on the brain. The 2021 National

*Correspondence: malosco@bu.edu

¹ Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Robinson Building, Suite B7800, Boston, MA 02118, USA

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Institute of Neurological Disorders and Stroke consensus diagnostic criteria for traumatic encephalopathy syndrome (TES) describe the clinical disorder associated with neuropathologically diagnosed CTE [10]. Impairments in memory and/or executive function are core cognitive features of the TES criteria. The specificity of these impairments to CTE and/or RHI is not clear as similar impairments are known to develop in other neurodegenerative diseases (e.g., Alzheimer's disease [AD], frontotemporal dementia) [11, 12]. The TES criteria are informed by retrospective reports from informants of brain donors [10, 13] and prospective objective neuropsychological data on individuals exposed to RHI is lacking. The patterns of cognitive impairments in populations at risk for CTE (e.g., former American football players) are not known. This has led to diagnostic challenges for neuropsychologists and other clinicians.

Neuropsychological evaluation is an integral component of the clinical evaluation of neurodegenerative diseases. This is evidenced by clinical diagnostic criteria for neurodegenerative diseases requiring the presence of cognitive impairment on neuropsychological testing [14–18], often defined by standardized test score(s) of 1 to 1.5 standard deviations below the normative mean [14, 17]. The TES research diagnostic criteria emphasize the need for comprehensive neuropsychological testing to substantiate the presence of cognitive impairment [10]. Neuropsychological test scores serve as outcome measures for large-scale multi-center clinical trials of disease-modifying therapies [19]. It is important that cognitive profiles of populations with exposure to RHI, such as former football players, are delineated for research and clinical purposes.

Research studies on the neuropsychological test performance of older former football players have been limited. Schaffert and colleagues conducted a critical review of 22 studies published between 2013 and 2019 on neuropsychological function in former National Football League (NFL) players [3]. Some, but not all, of the studies found evidence for cognitive impairment, most consistently in verbal episodic memory. There were inconsistencies in the domains impaired across studies. That review highlighted the limitations of the research on this topic that include (1) small sample sizes (e.g., $n = 9$ former NFL players); (2) unknown exposure status of the comparison groups; (3) lack of consistent reporting of effect sizes; (4) substantial variation in the extent and quality of the neuropsychological test battery and associated norming practices; and (5) restricted focus on former *professional* American football players.

The objective of this study was to characterize the neuropsychological test performance of a large sample of former college and professional football players from

the DIAGNOSE CTE Research Project [20]. Neuropsychological function across major cognitive domains was assessed and we report the sample raw and *T*-scores derived from age, sex, and/or education normative data. Rates of impairment by test and cognitive domain are reported.

Methods

Participants and study design

Participants were from the Diagnostics, Imaging, and Genetics Network for the Objective Study and Evaluation of Chronic Traumatic Encephalopathy (DIAGNOSE CTE) Research Project [20]. The objectives of the DIAGNOSE CTE Research Project are to develop in vivo biomarkers for CTE, characterize its clinical presentation, and refine and validate clinical research diagnostic criteria. The study enrolled 240 male participants, ages 45–74, including 120 former NFL players, 60 former college football players, and 60 asymptomatic men without a history of RHI or TBI. All participants volunteered to participate as a part of a research study and they were compensated \$500 for their time. Evaluations and participation were not done as part of clinical care or medico-legal purposes. Baseline evaluations were completed between September 2016 and February 2020. Inclusion criteria included no contraindications for MRI, lumbar puncture, or PET procedures; English as the primary language; and consent to all study procedures. Because RHI can often result in TBI, TBI was not exclusionary in the former football players. The former college football players must have played ≥ 6 years of organized football with ≥ 3 years at the college level. Former professional football players must have played ≥ 12 years of organized football, including ≥ 3 in college and ≥ 4 seasons in the NFL. Although recruitment for the former football players was *not* based on cognitive (or neuropsychiatric) status, most football players had subjective cognitive concerns at the time of study screening based on the AD8 Dementia Screening Interview and Cognitive Change Index (Supplemental Table 1).

The criteria for the asymptomatic unexposed were no self-reported diagnosed history of TBI of any severity at study screening; no participation in organized contact and collision sports (including American football), military combat, or any other activity that can result in RHI; absence of self-reported formal diagnosis or treatment of psychiatric illness or cognitive impairment; and no self-reported cognitive, behavioral, or mood symptoms at study telephone screening (Supplemental Table 1). They had to have a body mass index ≥ 24 in order to facilitate matching on body habitus to the former football players. All participants were required to have an informant and adequate decisional capacity at

the time of their baseline visit to participate. Additional details of enrollment criteria and recruitment methods have been reported [20]. The neuropsychological test performance of the unexposed asymptomatic men is presented and qualitatively described in the supplemental material (Supplemental Tables 2 and 3). These data are not presented in the main text, and statistical tests that compare the former American football players to the asymptomatic unexposed men on neuropsychological outcomes were not conducted because recruitment of participants for the DIAGNOSE CTE Research Project was based on our risk factor of interest (i.e., elite football play with RHI exposure) and symptoms (i.e., unexposed men must have been asymptomatic at screening). This recruitment strategy was designed for biomarker development [20]. However, it is problematic when examining clinical measures as outcomes because estimates of group differences are magnified.

Participants were evaluated at Boston University Chobanian & Avedisian School of Medicine (with MRI conducted at Brigham and Women's Hospital); Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Mayo Clinic Arizona (with PET scans at Banner Alzheimer's Institute); or NYU Langone Medical Center. Participants underwent a 2-day baseline study visit that included a comprehensive neuropsychological examination and other procedures. All sites received approval by their Institutional Review Board. Participants provided

written informed consent. Research was completed in accordance with the Helsinki Declaration.

Sample size

The final sample size included 59 former college football players and 111 former professional football players. (As shown in the supplement, there were 57 asymptomatic unexposed men.) The sample was reduced after exclusion of participants (across all study groups) for missing data on the primary objective neuropsychological tests ($n=5$) and suboptimal performance validity ($n=8$). Three had missing data on the Golden Stroop Color-Word Test due to colorblindness and were excluded from Golden Stroop Color-Word statistics but were not excluded otherwise.

Objective neuropsychological evaluation

Participants completed an in-person baseline neuropsychological test battery using standard paper-pencil tests administered by fully trained examiners [20]. A complete list of the domains assessed and neuropsychological tests administered are presented in Table 1.

Neuropsychological measures were selected to assure harmonization with data-sharing platforms, such as the National Alzheimer Coordinating Center (NACC). Many instruments and methodologies that overlap with the NACC Uniform Data Set (UDS) v.3.0 were selected [29, 30]. Measures include those that assess cognitive domains relevant to the features described in neuro-pathologically confirmed cases of CTE as reported by

Table 1 DIAGNOSE CTE Research Project Neuropsychological Baseline Measures

Domain	Test/instrument	Normative data source	Demographics used in normative data
Performance validity	Test of Memory Malingering	Tombaugh 1996 [21]	-
Est. premorbid intelligence	Wide Range Achievement Test-Fourth Edition Word Reading subtest	Wilkinson et al. 2006 [22]	Age
Learning and memory	Brief Visuospatial Memory Test-Revised (BVM-T-R)	Benedict 1997 [23]	Age
	Neuropsychological Assessment Battery (NAB) List Learning	Stern et al. [24]	Age, sex, Educ.
Executive function	Uniform Data Set (UDS) Craft Story 21 Recall	UDS v.3.0, June 2019	Age, sex, Educ.
	Controlled Oral Word Association Test	Tombaugh et al. 1999 [25]	Age, Educ.
	Golden Stroop Color and Word Interference Test (SCWT)	Golden et al. 2002 [26]	Age, Educ.
	NAB Mazes	Stern et al. [24]	Age, sex, Educ.
Attention, visual scanning, and psychomotor speed	Trail Making Test Part B	UDS v.3.0, June 2019	Age, sex, Educ.
	Symbol Digit Modalities Test	Smith 1973 [27]	Age, Educ
	Trail Making Test Part A	UDS v.3.0, June 2019	Age, sex, Educ.
Language	UDS Number Span Test	UDS v.3.0, June 2019	Age, sex, Educ.
	Animal Fluency	UDS v.3.0, June 2019	Age, Educ.
Visuospatial	UDS Multilingual Naming Test	UDS v.3.0, June 2019	Age, sex, Educ
	Judgment of Line Orientation (odd version)	Woodard et al. [28]	Age
	BVM-T-R Copy	Benedict 1997 [23]	-

Abbreviations: UDS Uniform Data Set, Educ education

informants of brain donors [5, 7, 10, 13] and that are part of the TES research diagnostic criteria [10, 13]. Domains assessed included attention, visual scanning, and psychomotor speed; executive functions; learning and episodic memory (verbal and visual); language; and visuospatial abilities. Tests of memory and executive functions were overrepresented given these domains are known to be adversely affected by exposure to RHI [3, 10, 13]. Measures of performance validity and estimated pre-morbid intelligence were administered. Raw scores for all tests were generated according to NACC or test manual protocols. For all tests, the primary raw score outcome was total correct with the exception of Trail Making Test where completion time (in seconds) served as the primary outcome (number of errors is also reported). Neuropsychological test raw scores were converted to *T*-scores using normative data that accounted for age, sex, and education. A small number of tests only accounted for age or age and education. Table 1 provides the normative data source. A *T*-score ≤ 35 (i.e., 1.5 standard deviations [SD] below the normative mean) was considered impaired [14, 17, 31]. The *T*-score range was restricted to 20–80 to limit skewed distributions of the data and outliers.

Suboptimal performance validity was defined by below criterion performance on two out of the following three performance validity measures: Trial 2 of the Test of Memory Malingering (TOMM), reliable number span (modified due to use of the UDS Number Span task), and Neuropsychological Assessment Battery (NAB) List Learning Recognition Hits. Established cutoffs for defining performance validity failure on these measures were used but are not disclosed here to preserve test integrity. While failure of one performance validity test can be indicative of invalidity [32], our decision adheres to the revised Slick criteria (Sherman et al.) for identification of malingered neurocognitive dysfunction that advises failure of 2+ performance validity tests [33]. Of the sample with complete neuropsychological data, 10 (4.2%) had suboptimal performance on the TOMM, 8 (3.4%) had a below cutoff score on the reliable number span, and 50 (21.3%) fell below cutoff on the NAB Recognition Hits trial. Fifty (21.3%) failed at least one performance validity measure, six (2.6%) failed two, and only 2 (0.9%) failed all three. Of note, four participants had one performance validity test missing but were above the cutoff on the other two indices. Taken together, for the current sample, a total of 8 participants were excluded for suboptimal performance validity.

Sample characteristics

Semi-structured interviews were performed, supplemented by online questionnaires, to collect data on

demographics, medical and psychiatric history, athletic history, and other variables not relevant to the present study. An aliquot of whole blood was used for *APOE* genotyping. Race and ethnicity were self-reported. A majority of the sample was Black or White. There was insufficient representation of other racial groups to statistically examine them separately. All racial groups are presented in Table 2.

Statistical analyses

Descriptive statistics were used to characterize the neuropsychological test raw and *T*-scores. Rates of impairment on each test and/or test indices are reported, based on above-described cutoffs (e.g., *T*-score ≤ 35). A neuropsychological domain was considered impaired if at least two tests within that domain had a *T*-score ≤ 35 . This was only done for the attention, visual scanning, psychomotor speed domain, executive function domain, and the episodic memory domain as there was insufficient number of tests for the language and visuospatial domains (as designed). While we report the frequency of those who had one impaired score, our interpretation of an impaired domain is based on 2+ tests falling below the threshold given the high base rates of test impairments on large batteries among normative individuals [31, 35]. For the memory domain, measures that counted towards impairment included the long delay recall trials from the Brief Visuospatial Memory Test-Revised, Neuropsychological Assessment Battery List Learning task, and Craft Story 21 Recall (Paraphrase). Analysis of covariance controlling for age compared the former college and professional football players on the neuropsychological test raw scores. Statistical analyses were conducted using IBM SPSS Statistics, version 27.

Results

Sample characteristics are in Table 2. The sample included 170 former American football players (111 former professional football players, 59 former college football players). The sample of football players was 57.5 (SD=8.1) years old and had 16.7 (SD = 1.5) years of education, and 55 (32.4%) were Black or African American. Tables 3 and 4 show the neuropsychological test performance of the former American football players. Analysis of covariance controlling for age showed a statistically significant difference between the former college and professional football player groups on only three of the primary neuropsychological tests, all memory (Supplemental Tables 4 and 5), though the significant differences would not have survived multiple comparison adjustments. For this reason, the former college and professional American football players were combined and described as a single group.

Table 2 Sample characteristics

	Former football players (n = 170)	Former professional (n = 111)	Former college (n = 59)	Asymptomatic unexposed men (n = 57)	P-value ^d
Demographics					
Age, mean (SD) years	57.5 (8.1)	59.6 (7.6)	53.6 (7.7)	59.2 (8.3)	0.17
Education, mean (SD) years	16.7 (1.5)	16.6 (1.1)	17.0 (1.9)	17.4 (3.4)	0.14
Race ^a , n (%)					0.58
American Indian or Alaska Native	1.0 (0.6)	1.0 (0.9)	0.0	0.0	
Black or African American	55.0 (32.4)	45.0 (40.5)	10.0 (16.9)	21.0 (36.8)	
Native Hawaiian or other Pacific Islander	0.0	0.0	0.0	1.0 (1.8)	
White	110 (64.7)	63.0 (56.8)	47.0 (79.7)	35 (61.4)	
Multiple races	2.0 (1.2)	1.0 (0.9)	1.0 (1.7)	0.0	
Not reported	2.0 (1.2)	1.0 (0.9)	1.0 (1.7)	0.0	
Ethnicity, n (%)					--
Hispanic or Latino	3.0 (1.8)	3.0 (2.7)	0.0	0.0	
Body mass index , mean (SD) kg/m ²	32.5 (4.5)	31.8 (4.3)	33.7 (4.8)	30.8 (4.6)	0.02
Neurodevelopment					
Attention-deficit/hyperactivity disorder, n (%)	14.0 (8.2)	5.0 (4.5)	9.0 (15.3)	1.0 (1.8)	--
Learning disability, n (%)	5.0 (2.9)	2.0 (1.8)	3.0 (5.1)	0.0	--
Athletic					
Total years of football, mean (SD) years	15.8 (4.4)	18.0 (3.3)	11.5 (2.6)	-	--
Age of first exposure to football, mean (SD) years	11.1 (2.8)	11.6 (2.7)	10.2 (2.6)	-	--
Primary position at highest level of play, n (%)					--
Offensive lineman	42.0 (24.7)	20.0 (18.0)	22.0 (37.3)	-	
Offensive back or receiver	44.0 (25.9)	31.0 (27.9)	13.0 (22.0)	-	
Defensive lineman	19.0 (11.2)	14.0 (12.6)	5.0 (8.5)	-	
Linebacker	27.0 (15.9)	20.0 (18.0)	7.0 (11.9)	-	
Defensive back	34.0 (20.0)	22.0 (19.8)	12.0 (20.3)	-	
Special teams	4.0 (2.4)	4.0 (3.6)	0.0	-	
Reported number of post-definition concussions, median (IQR) ^b	30 (88)	30 (88)	25 (88)	--	--
APOE genotype					
ε4 carrier ^c , n (%)	49.0 (28.8)	30.0 (27.0)	19.0 (32.2)	11.0 (19.3)	0.21

The sample excluded participants who had suboptimal performance on 2+ performance validity tests and was restricted to participants who had complete data on all primary objective neuropsychological tests (n = 13 with missing data [9 former professional, 1 former college, 3 asymptomatic unexposed men])

^a n = 2 with missing data (2 former professional)

^b All participants were read a definition of concussion prior to being asked to estimate their total number of concussions [34] (n=1 with missing data, former professional football player)

^c n = 9 with missing data (4 former professional, 1 former college, 4 asymptomatic unexposed men)

^d Independent samples t-test compared the former American football players and the asymptomatic unexposed men on continuous outcomes and chi-square was used for binary outcomes

As previously described, participants who had suboptimal performance validity on 2+ measures were excluded from the sample (n=8). However, there remained four participants who had suboptimal scores on TOMM Trial 2 (scores ranged from 32 to 38). These four participants were retained given their adequate performances on the other two validity tests, including reliable number span (scores ranged from 7 to 11) and NAB List Learning Recognition Hits (percentiles ranged from 13 to 50).

Estimated premorbid intelligence

Based on the Wide Range Achievement Test, 4th Edition (WRAT-4) standard score, the estimated premorbid intelligence of the former football players fell in the average psychometric range. Fourteen had below average standard scores (i.e., <85). Five (2.9%) reported a diagnostic history of a learning disability, two of whom had a below average standard score on the WRAT-4.

Table 3 Baseline neuropsychological test performance of former American football players

Domain	Test/instrument	Former American football players (n = 170)			
		Raw			T-score Mean (SD)
		Mean (SD)	Min	Max	
Performance validity	TOMM Trial 2	49.5 (2.4)	32	50	-
	UDS Reliable Number Span	9.9 (2)	6	16	-
	NAB List Learning Recognition	10.4 (1.4)	6	12	37.3%ile (28.2) ^a
Est. premorbid intelligence	WRAT-4 ^{b,c}	62.4 (5.5)	39	70	102.9 (12.7) ^b
Learning and memory	BVMT-R Trials 1–3	20.9 (7.2)	6	35	46.3 (12.6)
	BVMT-R delayed recall	8.6 (2.8)	0	12	49.8 (12.5)
	NAB List Learning trials 1–3	19.6 (4.7)	9	31	40.4 (9.3)
	NAB List Learning SDR	5.7 (2.6)	0	11	39.6 (12.1)
	NAB List Learning LDR	5.2 (2.9)	0	11	38.8 (12.5)
	Craft Story Immediate (Verbatim)	18.8 (6.1)	1	33	44.3 (9.1)
	Craft Story Immediate (Paraphrase)	14.7 (3.9)	1	24	44.8 (9.6)
	Craft Story Delay (Verbatim)	15.7 (6.1)	0	30	43 (9.2)
	Craft Story Delay (Paraphrase)	13.1 (4.2)	0	21	43.2 (9.8)
	Executive function	COWAT	41.2 (11.4)	3	76
SCWT Interference ^d		36.6 (9.7)	11	67	48.4 (6.6)
NAB Mazes		16.0 (6.2)	2	26	53.9 (10.2)
Trail Making Test Part B		80.4 (43.4)	29	300	44.7 (10.6)
Trail Making Test Part B errors		0.6 (0.9)	0	4	-
Attention, visual scanning, and psychomotor speed	Symbol Digit Modalities Test	47.4 (9.6)	24	75	48.4 (10.3)
	Trail Making Test Part A	30.2 (10.6)	12	72	44.5 (10.3)
	Trail Making Test Part A errors	0.2 (0.4)	0	2	-
	UDS Number Span Test: Forward	8.5 (2.1)	3	14	49.2 (8.8)
	UDS Number Span Test: FL	6.8 (1.2)	4	9	49.6 (9.6)
	UDS Number Span Test: Backward	6.8 (2.2)	2	13	46.2 (10.1)
	UDS Number Span Test: BL	4.9 (1.3)	2	8	46.2 (10)
Language	Animal Fluency	21 (5.4)	6	35	46 (9.4)
	Multilingual Naming Test	29.2 (2.5)	7	32	43.5 (9.9)
Visuospatial ability	Judgment of Line Orientation (odd version)	12.7 (2.3)	5	15	53 (9.9)
	BVMT-R Copy ^a	11.7 (0.7)	9	12	-

The sample excluded participants who had suboptimal performance on 2+ performance validity tests and was restricted to participants who had complete data on all primary objective neuropsychological tests (across all DIAGNOSE CTE Research Project study groups)

Abbreviations: TOMM Test of Memory Malingerer, RH Recognition Hits, WRAT-4 Wide Range Achievement Test-Fourth Edition Word Reading, BVMT-R Brief Visuospatial Memory Test-Revised, NAB Neuropsychological Assessment Battery List Learning [SDR Short Delay Recall, LDR Long Delay Recall], UDS Uniform Data Set, COWAT Controlled Oral Word Association Test, SCWT Golden Stroop Color and Word Test, FL Forward Longest Span, BL Backward Longest Span

^a Percentile reported

^b n = 1 former football player with missing data for WRAT-4 and BVMT-R Copy

^c Standard score reported for WRAT-4

^d n = 2 with missing data due to colorblindness

Learning and episodic memory

The sample mean T-scores for NAB List Learning Trials 1–3 and NAB List Learning Short and Long Delay recall trials were all ~40. Thirty-six (21.2%) had impaired episodic memory, representing the domain with the highest rates of impairment. Eighty-eight (51.8%) had at least one test impaired in episodic memory. Of the sample, impairments were frequent on the

NAB List Learning Trials 1–3 (30.6%, n=52) and on the NAB List Learning Short Delay (37.6%, n=64) and Long Delay recall trials (44.7%, n=74). The participants recalled a mean of 5.2 (of 12) words after a long delay recall. On the recognition trial, 23 participants (13.8%) had impaired false positive errors (mean = 4.8, SD = 3.8) and 33 participants (19.8%) had impaired recognition hits (mean = 10.4, SD = 1.4).

Table 4 *T*-score distributions of baseline neuropsychological test performance of former American football players

Domain	Test/instrument	Former American football players (<i>n</i> = 170), <i>n</i> (%)			
		≤ 35	36–39	40–49	≥ 50
Learning and memory	BVMT-R Trials 1–3	37 (21.8)	16 (9.4)	44 (25.9)	73 (42.9)
	BVMT-R delayed recall	29 (17.1)	6 (3.5)	41 (24.1)	94 (55.3)
	NAB List Learning trials 1–3	52 (30.6)	19 (11.2)	71 (41.8)	28 (16.5)
	NAB List Learning SDR	64 (37.6)	32 (18.8)	35 (20.6)	39 (22.9)
	NAB List Learning LDR	76 (44.7)	10 (5.9)	47 (27.6)	37 (21.8)
	Craft Story Immediate (Verbatim)	25 (14.7)	25 (14.7)	73 (42.9)	47 (27.6)
	Craft Story Immediate (Paraphrase)	27 (15.9)	19 (11.2)	69 (40.6)	55 (32.4)
	Craft Story Delay (Verbatim)	26 (15.3)	28 (16.5)	78 (45.9)	38 (22.4)
	Craft Story Delay (Paraphrase)	32 (18.8)	16 (9.4)	73 (42.9)	49 (28.8)
Executive function	COWAT	11 (6.5)	23 (13.5)	69 (40.6)	67 (39.4)
	SCWT Interference ^a	6 (3.6)	9 (5.4)	82 (48.8)	71 (42.3)
	NAB Mazes	7 (4.1)	8 (4.7)	41 (24.1)	114 (67.1)
	Trail Making Test Part B	35 (20.6)	12 (7.1)	58 (34.1)	65 (38.2)
Attention, visual scanning, and psychomotor speed	Symbol Digit Modalities Test	20 (11.8)	9 (5.3)	56 (32.9)	85 (50)
	Trail Making Test Part A	32 (18.8)	10 (5.9)	65 (38.2)	63 (37.1)
	UDS Number Span Test: Forward	4 (2.4)	15 (8.8)	74 (43.5)	77 (45.3)
	UDS Number Span Test: FL	14 (8.2)	10 (5.9)	57 (33.5)	89 (52.4)
	UDS Number Span Test: Backward	25 (14.7)	24 (14.1)	62 (36.5)	59 (34.7)
	UDS Number Span Test: BL	24 (14.1)	6 (3.5)	89 (52.4)	51 (30)
Language	Animal Fluency	29 (17.1)	16 (9.4)	71 (41.8)	54 (31.8)
	Multilingual Naming Test	36 (21.2)	18 (10.6)	77 (45.3)	39 (22.9)
Visuospatial	Judgment of Line Orientation (odd version)	12 (7.1)	6 (3.5)	27 (15.9)	125 (73.5)

The sample excluded participants who had suboptimal performance on 2+ performance validity tests and was restricted to participants who had complete data on all primary objective neuropsychological tests

Abbreviations: *BVMT-R* Brief Visuospatial Memory Test-Revised, *NAB* Neuropsychological Assessment Battery List Learning [*SDR* Short Delay Recall, *LDR* Long Delay Recall], *UDS* Uniform Data Set, *COWAT* Controlled Oral Word Association Test, *SCWT* Golden Stroop Color and Word Test, *FL* Forward Longest Span, *BL* Backward Longest Span

^a *n* = 2 with missing data due to colorblindness

Compared with learning and memory for unstructured verbal stimuli, learning and memory of structured contextualized information (i.e., a story) were better. The sample mean *T*-scores were in the average psychometric range for Craft Story 21 Immediate and Delay Recall trials (for both paraphrase and verbatim). Rates of impairments were approximately 15% (*n*=25) for Craft Story 21 Recall Immediate and Delay trials with impairment rates highest for Craft Story 21 Recall Delay Paraphrase (18.8%, *n*=32).

There was better visual than verbal memory test performance. The sample mean *T*-scores on indices of learning and episodic memory for figures (BVMT-R) fell in the average psychometric range. Of the sample, 21.8% (*n*=37) and 17.1% (*n*=29) had impairments on BVMT-R Trials 1–3 and BVMT-R Delay Recall, respectively. Recognition hits (mean = 5.7, *SD* = 0.7) and false alarms (mean, *SD* = 0.1, 0.4) were overall intact with few participants having scores in the impaired range (*n* = 6 [3.5%] for hits, *n* = 4 [2.4%] for false alarms).

Executive functions

Mean *T*-scores were in the average psychometric range and 12 (7.1%) had impaired executive function. Forty-five (26.5%) had a least one test impaired in this domain. Rates of impairments were highest for Trail Making Test Part B (20.6%). On Trail Making Test Part B, 37 had one error, 14 had two errors, and 9 had 2+ errors. Less than 10% of the sample had impaired performance across all other tests.

Attention, visual scanning, psychomotor speed

The sample mean *T*-scores fell in the average psychometric range for all neuropsychological tests administered in this domain. Twenty-one (12.4%) participants were impaired. Fifty-five (32.4%) had one test impaired and rates of impairments ranged from 2.4% (*n*=4) on UDS Number Span Forward total correct trials to 18.8% (*n*=32) on Trail Making Test Part A. On Trail Making Test Part A, 29 participants had one error and two participants had two errors.

Language

The sample mean *T*-scores for measures of semantic fluency (Animal Fluency) and confrontation naming (Multilingual Naming Test, MINT) were in the average psychometric range. Regarding rates of impairments, 21.2% ($n=36$) and 17.1% ($n=29$) of the sample were impaired on the MINT and Animal Fluency, respectively.

Visuospatial

Only 7.1% ($n=12$) were impaired on the Judgment of Line Orientation test. Gross visuospatial abilities on the BVMT-R Copy were intact as raw scores ranged from 9 to 12 (of 12).

Multidomain impairments

We examined rates of multidomain impairments among the memory, attention, visual scanning and psychomotor speed, and executive function domains. Based on our definition of impairment (i.e., 2+ tests impaired), 25 (14.7%) had 1 domain impaired and 20 (11.8%) of the football players had 2 or more domains that were impaired.

Discussion

This study examined the neuropsychological test performance of 170 male former college ($n=59$) and professional ($n=111$) football players (ages 45–74), most of whom had subjective cognitive concerns. Impairments were identified using established normative data that account for age, sex, and education. Episodic memory was the most frequently impaired cognitive domain, particularly memory of unstructured verbal information (i.e., NAB List Learning). Compared with unstructured verbal stimuli, learning and recall of contextual verbal stimuli (i.e., Craft stories) and visual information (i.e., BVMT-R figures) were better but impairments still frequent. Other domains with impairments included attention and psychomotor speed (i.e., Trail Making Test Part A) and set-shifting and mental flexibility (Trail Making Test Part B). With the exception of Trail Making Test Part B, performances on tests of executive functions and on visual-perceptual abilities were otherwise preserved.

The results of this study have several implications. Previous research has shown that more than one-third of NFL retirees report being “extremely concerned” about memory and thinking skills [36]. A majority of this sample also had subjective cognitive concerns. Our finding that performance on memory tests was the most frequently impaired is similar to other neuropsychological studies of former NFL players [3]. The mean performance of the word list learning test was at a level of impairment comparable to what is seen in patients with mild cognitive impairment (MCI) [37]. This finding, in combination with less significant reductions on scores on

psychomotor speed, confrontation naming, and semantic fluency suggests a neuropsychological profile that resembles an amnesic form of MCI in this sample of former college and professional football players with a mean age of 58, similar to what has been suggested by other investigators [38].

The 2021 NINDS Consensus Diagnostic Criteria for TES include impairments in episodic memory and/or executive functions as core clinical features [10]. One surprising result from this study was that, with the exception of Trail Making Test Part B, performance on tests of executive functions was relatively preserved. While this finding might provide additional support for a neurocognitive profile consistent with amnesic MCI, it might also be an effect of some of the well-known limitations in the neuropsychological assessment of executive functions. Studies that have examined many of the most commonly used tests of executive functions find only modest correlations among the tests suggesting that these functions are difficult to measure as they do not combine neatly into a unitary factor [39]. There are also indications that tests of executive functions often fail to correspond to behavioral ratings of dysexecutive behavior, raising questions about the ecological validity of the measures [40]. In theory, one would expect individuals with the “neurobehavioral dysregulation” of TES to be impaired most specifically on measures of impulsive responding. There was no evidence of impairment in this study on tasks like the Golden Stroop Color Word Interference measure, a well-known index of cognitive impulsivity.

This study included former college and professional football players. There was no statistically significant difference (with consideration of multiple comparisons) between the former college and professional American football players across any of the neuropsychological tests, but there were trends for worse performance in former professional football players. Former professional American football players, and primarily former NFL players, have been the focus of studies on the long-term neuropsychological consequences of American football play [3]. This is one of the first studies to feature middle aged to older adult former *college* football players without subsequent professional experience or other RHI exposure after college. From a public health perspective, it is critical to elucidate the long-term health outcomes of college football players given that approximately 800,000 student athletes have played college football in the USA since 1960, 250,000 of whom are currently older than 60 years of age [41]. Moreover, a recent health outcome survey study found a significantly higher prevalence of cognitive impairment disorders in former college football players compared to the general population, a finding similar to previous studies of former NFL players [41].

A challenge in the field of neuropsychology is the appropriate selection of normative data to derive standardized scores to establish levels of impairment. Here, normative data used included those from the specific test manuals, as well as from the NACC for UDS measures. A majority of normative data accounted for age, sex, and education. However, there were variations in normative adjustments across tests that could have influenced impairment rates by test and domain. Race-based norming was *not* performed. Race-based norming has been incorporated into the training and practice of neuropsychology since at least the 1990s (e.g., Heaton Norms) based on the assumption that race may be a proxy for socioeconomic factors associated with cognitive function. For people who identify as Black, race-based norming results in a stricter threshold needed to be designated as cognitively impaired compared with Whites. The differential treatment of Blacks when scoring and interpreting neuropsychological tests has been a controversial practice [42]. Recently, the NFL ended its use of race-based neuropsychological test norms to determine monetary compensation as part of the NFL Concussion Settlement. The use of race-based norms as part of a rigid algorithm that is void of clinical judgment to determine compensation perpetuates systemic racial injustice and inequity [43]. Prior to consideration of normative data, a majority of neuropsychological tests were developed in White populations, placing Black Americans at initial disadvantage from the beginning. A study is currently underway that is modeling the neuropsychological differences by race in this sample, along with relevant psychosocial, socioeconomic, social, and health factors that might explain observed differences.

There are limitations to the present findings. The asymptomatic unexposed men were required to have no reported symptoms to be eligible for the DIAGNOSE CTE Research Project. While recruitment of the former football players was not based on symptomatic status, most have subjective cognitive (and neuropsychiatric) concerns. This design is appropriate for biomarker development but it limits meaningful comparisons and interpretations on neuropsychological measures between groups as any observed differences could be biased by our recruitment methods. For this reason, statistical comparisons of the former American football players and the asymptomatic unexposed men were not performed [20]. The use of normative data circumvents limitations of study design and informs on rates of neuropsychological impairments among former elite football players. Our ability to make inferences on whether impairments are from pathology and a function of exposure to RHI is challenging given the recruitment design, lack of biomarkers, and in the context of the test performance of

the asymptomatic unexposed men. Although impairments were generally infrequent in the unexposed men, approximately 25% and 21% were impaired on BVMT-R Learning Trials and NAB List Learning Long Delay Recall trial, respectively. While the presence of neurological disease in this group cannot be ruled out, it might also be a function of the number of neuropsychological tests administered [31, 44–46]. In the present battery of close to 15 separate correlated indices, rates of impairments in the entire sample might be inflated due to type I error. We also excluded eight participants who had evidence of suboptimal performance on 2+ performance validity tests, based on the revised Slick criteria [33]. Four participants in the sample had suboptimal performance on the TOMM Trial 2 but not on any of the remaining validity indices. We acknowledge that failure of just one validity test can be indicative of invalidity and could have contributed to inflated impairment rates [32]. However, the use of 2+ tests to define invalidity is more stringent, followed recommended guidelines, and performance invalidity rates in this sample were overall low and did not influence the results.

The current study did not include a disease comparison group (e.g., Alzheimer's disease), which is needed to determine the specificity of the observed neuropsychological profiles and facilitate differential diagnosis. The sample includes individuals who volunteered to participate in research. Most of the male former football players had concerns about their cognitive function, mood, and/or behavior. External validity to the general football population, as well as to women and other athlete populations is limited. We used 1.5 SD below the normative mean to define impairment, a generally accepted convention [14, 17]. We recognize that a continuum exists. Finally, cognitive function was measured using traditional paper-and-pencil tests that might have lacked adequate sensitivity to capture certain impairments. The absence or low rate of impairments in certain domains (e.g., executive functions, visuospatial abilities) might be related to measurement. While digital phenotyping currently lacks clinical applicability, it is an exciting avenue of future research.

Conclusions

In this sample of 170 male former elite American football players, a comprehensive neuropsychological assessment revealed most frequent impairments in learning and recall for unstructured verbal stimuli. Continued efforts are needed to characterize the neuropsychological profile of individuals exposed to RHI to assist neuropsychologists and other clinicians in disease detection and differential diagnosis. Additional research that includes a disease comparison (e.g., Alzheimer's disease) and

examines causes of neuropsychological impairment in this population is needed. Development of tests sensitive to the specific executive functions disturbed in this population is also an important target for future research. Such development should include and extend beyond traditional paper-and-pencil tests which might not be adequate for the identification of certain impairments in this population.

Abbreviations

AD: Alzheimer's disease; BVMT-R: Brief Visuospatial Memory Test-Revised Version; CTE: Chronic traumatic encephalopathy; FTD: Frontotemporal dementia; MCI: Mild cognitive impairment; NAB: Neuropsychological Assessment Battery; NACC: National Alzheimer's Coordinating Center; NFL: National Football League; PET: Positron emission tomography; RHI: Repetitive head impacts; SD: Standard deviation; TES: Traumatic encephalopathy syndrome; TOMM: Test of Memory Malingering; UDS: Uniform Data Set; WRAT-4: Wide Range Achievement Test, 4th Edition.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13195-022-01147-9>.

Additional file 1: Supplemental Table 1. Self- and Informant-Reported Symptomatic Status of Participants at Time of Study Screening. **Supplemental Table 2.** Baseline Neuropsychological Test Performance of the Asymptomatic Unexposed Men. **Supplemental Table 3.** T-Score Distributions of Baseline Neuropsychological Test Performance of the Asymptomatic Unexposed Men. **Supplemental Table 4.** Baseline Neuropsychological Test Performance of the Former College and Professional Football Players. **Supplemental Table 5.** T-Score Distributions of Baseline Neuropsychological Test Performance for Former College and Professional Football Players.

Acknowledgements

The DIAGNOSE CTE Research Project Current and Former Investigators and Key Personnel

Banner Alzheimer's Institute

Investigators

Eric Reiman, M.D. (Co-PI)

Yi Su, Ph.D.

Kewei Chen, Ph.D.

Hillary Protas, Ph.D.

Non-Investigators

Connie Boker, M.B.A. (Director, Imaging Center Operations)

Boston University School of Medicine

Investigators

Michael L. Alosco, Ph.D.

Rhoda Au, Ph.D.

Robert C. Cantu, Ph.D.

Lindsay Farrer, Ph.D.

Robert Helm, M.D. *

Douglas I. Katz, M.D.

Neil Kowall, M.D. *

Jesse Mez, M.D.

Gustavo Mercier, M.D., Ph.D. *

James Otis, M.D. *

Robert A. Stern, Ph.D. (Co-PI)

Jason Weller, M.D.

Non-Investigators

Irene Simkin, M.S. (Lab Manager, Molecular Genetics Core Facility)

Boston University Project Coordinating Center Staff

Alondra Andino, B.A. (Project Administrative Manager) *

Shannon Conneely, B.A. (Site Coordinator) *

Courtney Diamond, M.B.A. (Project Manager) *

Tessa Fagle, B.A. (Research Assistant)

Olivia Haller, B.A. (Recruitment Coordinator) *

Tennyson Hunt, M.B.A. (Project Administrative Manager) *

Nicole Gullotti, M.B.A. (Research Administrator) *

Megan Mariani, B.S., B.A. (Project Manager)

Brian Mayville, B.S. (Site Coordinator)

Kathleen McLaughlin, B.A. (Research Assistant)

Mary Nanna, B.A. (Retention Coordinator)

Taylor Platt, M.P.H. (Recruitment Coordinator) *

Surya Pulukuri, B.A. (Research Assistant)

Fiona Rice, M.P.H. (Project Manager) *

Madison Sestak, B.S. (Assistant Recruitment Coordinator) *

Boston University School of Public Health

Investigators

Michael McClean, Sc.D.

Yorghos Tripodis, Ph.D.

Data Team Staff

Douglas Annis, M.S. (Systems Analyst) *

Christine Chaisson, M.P.H. (Leader of Data Management Sub-team) *

Diane B. Dixon (Project Manager)

Carolyn Finney, B.A. (Data Manager)

Kerrin Gallagher, M.P.H. (Statistical Analyst) *

Kaitlin Hartlage, M.P.H. (Statistical Analyst)

Jun Lu, M.S. (Data Security and Technology Analyst)

Brett Martin, M.S. (Statistical Manager)

Emmanuel Ojo, M.P.H. (Statistical Analyst) *

Joseph N. Palmisano, M.A., M.P.H. (Leader of Data Management Sub-team)

Brittany Pine, B.A., B.S. (Statistical Analyst)

Janani Ramachandran, M.S. (Data Manager)

Brigham and Women's Hospital

Investigators

Sylvain Bouix, Ph.D.

Jennifer Fitzsimmons, M.D. *

Alexander P. Lin, Ph.D.

Inga K. Koerte, M.D., Ph.D.

Ofer Pasternak, Ph.D.

Martha E. Shenton, Ph.D. (Co-PI)

Non-Investigators

Hector Arciniega, Ph.D. (Postdoctoral Research Fellow)

Tashrif Billah, M.S. (Software Engineer)

Elena Bonke, M.S. (Ph.D. Student)

Katherine Breedlove, Ph.D. (Postdoctoral Research Fellow)

Eduardo Coello, Ph.D. (Postdoctoral Research Fellow)

Michael J. Coleman, M.A. (Senior Scientist)

Leonhard Jung, (Ph.D. Student)

Huijun Liao, B.S. (Study Coordinator)

Maria Loy, M.B.A., M.P.H. (Senior Program Coordinator)

Elizabeth Rizzoni, B.A. (Research Assistant)

Vivian Schultz, M.D. (Postdoctoral Research Fellow)

Annelise Silva, B.S. (Research Assistant) *

Brynn Vessey, B.S. (Research Assistant)

Tim L.T. Wiegand, (Ph.D. Student)

Cleveland Clinic Lou Ruvo Center for Brain Health

Investigators

Sarah Banks, Ph.D. (Now at University of California, San Diego)

Charles Bernick, M.D. (Now at University of Washington)

Justin Miller, Ph.D.

Aaron Ritter, M.D.

Marwan Sabbagh, M.D. *

Non-Investigators

Raelynn de la Cruz, (Psychometrician)*

Jan Durant, (Psychometrician)*

Morgan Golceker (Site Coordinator)

Nicolette Harmon, (Site Coordinator) *

Kaeson Kaylegian, (Psychometrician)*

Rachelle Long, (Site Coordinator) *

Christin Nance, (Psychometrician)*
Priscilla Sandoval (Site Coordinator) *

George Washington University School of Medicine and Health Sciences

Investigator
Robert W. Turner, Ph.D.

Inivcro (formerly Molecular Neuroimaging)

Investigator
Kenneth L. Marek, M.D.
Non-Investigator
Andrew Serrano, M.B.A.

Mayo Clinic Arizona

Investigators
Charles H. Adler, M.D., Ph.D.,
David W. Dodick, M.D.
Yonas Geda, M.D., MSc (Now at Barrow Neurological Institute)
Jennifer V. Wethe, Ph.D.
Non-Investigators
Bryce Falk, R.N.
Amy Duffy, (Site Coordinator) *
Marc Howard, (Psychometrician)*
Michelle Montague, (Psychometrician)*
Thomas Osgood, (Site Coordinator)

National Institute of Neurological Disorders and Stroke (NINDS)

Debra Babcock, M.D., Ph.D. (Scientific Program Official)
Patrick Bellgowan, Ph.D. (Administrative Program Official)*

New York University:

Investigators
Laura Balcer, M.D., M.S.C.E.
William Barr, Ph.D.
Judith Goldberg, Sc.D.
Thomas Wisniewski, M.D. *
Ivan Kirov, Ph.D.
Yvonne Lui, M.D.
Charles Marmar, M.D.
Non-Investigators
Lisena Hasanaj (Site Coordinator)
Liliana Serrano
Alhassan Al-Kharafi (Psychometrician)*
Allan George (Psychometrician)*
Sammie Martin (Psychometrician)*
Edward Riley (Psychometrician)*
William Runge (Psychometrician)*

University of Nevada, Las Vegas

Jeffrey L. Cummings, M.D., ScD (Co-PI)

University of Washington and VA Puget Sound

Investigator
Elaine R. Peskind, M.D.
Non-Investigator
Elizabeth Colasurdo (Lab Manager)

Washington University (CNSA)

Investigators
Daniel S. Marcus, Ph.D.
Non-Investigator
Jenny Gurney, M.S.

Consultants

Richard Greenwald, Ph.D. (Simbex)*
Keith A. Johnson, M.D. (Massachusetts General Hospital)
*No longer involved in project.

Authors' contributions

MLA, WBB, and RAS designed the study and drafted the manuscript. MLA, WBB, SVP, JC, YT, and MM analyzed and interpreted the data as well as assisted

with the presentation of the data. YT, JNP, BM, KH, and SVP assisted with data set creation and management. Roles in data acquisition included MLA, WBB, SJB, JVV, SVP, CHA, LJB, MLM, JLC, EMR, MES, and RAS. JLC, EMR, MES, and RAS conceived the overall study design of the DIAGNOSE CTE Research Project. All authors critically read and helped to revise the manuscript and assisted with the interpretation of the data. All authors approved the submitted version and agree to be accountable for the work.

Funding

This work was supported by grants from the National Institutes of Health (U01NS093334; P30AG072980; R01NS078337; K23NS102399; P30AG019610; K01AG054762; R01NS100952; RF1NS122854). This publication was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through BU-CTSI Grant Number 1UL1TR001430. The primary funding source is the National Institute of Neurological Disorders and Stroke (NINDS), through a U01 Research Project Cooperative Agreement (U01NS093334).

Availability of data and materials

The datasets generated and analyzed during the current study will be available in the Federal Interagency Traumatic Brain Injury Research (FITBIR) repository, <https://fitbir.nih.gov>. Datasets will also be available through a data-sharing portal for the DIAGNOSE CTE Research Project, <http://diagnosecte.com>. It is also anticipated that study datasets will be available in the Global Alzheimer's Association Interactive Network (GAAIN) repository, <http://www.gaain.org>.

Declarations

Ethics approval and consent to participate

All Participant Evaluation Sites received approval by their respective Institutional Review Boards. All participants provide written informed consent during their baseline and follow-up study visits.

Consent for publication

Not applicable.

Competing interests

CHA consulted for Avion, CND Life Sciences, Jazz, and Precon Health. LJB is Editor-in-Chief of the *Journal of Neuro-Ophthalmology* and is a paid consultant to Biogen (Cambridge, MA, USA). CB receives research support from the Ultimate Fighting Championship, Top Rank promotions, Haymon Boxing, Las Vegas Raiders, and Professional Bull Riders. He is a paid consultant for Aurora Concussion Therapy Systems, Inc. (St. Paul, MN). RA is a paid consultant to Biogen (Cambridge, MA, USA) and serves on the Scientific Advisory Board of Signant Health (Blue Bell, PA). WBB provides expert witness testimony in legal cases involving concussion and CTE. DWD reports the following conflicts: consulting: Amgen, CapiThera, Cerecin, Ceruvia Lifesciences, Cooltech, Ctrl M, Allergan, Abbvie, Biohaven, GSK, Lundbeck, Eli Lilly, Novartis, Impel, Satsuma, Theranica, WL Gore, Genentech, Nocira, Perfood, Praxis, Pfizer, AYYA Biosciences, and Revance; honoraria/expense reimbursement/royalties: American Academy of Neurology, Headache Cooperative of the Pacific, MF Med Ed Research, Biopharm Communications, CEA Group Holding Company (Clinical Education Alliance LLC), Teva (speaking), Amgen (speaking), Eli Lilly (speaking), Lundbeck (speaking), Vector psychometric Group, Clinical Care Solutions, CME Outfitters, Curry Rockefeller Group, DeepBench, Global Access Meetings, KLJ Associates, Academy for Continued Healthcare Learning, Majallin LLC, Medlogix Communications, Medica Communications LLC, MJH Lifesciences, Miller Medical Communications, Synapse, WebMD Health/Medscape, Wolters Kluwer, Oxford University Press, and Cambridge University Press; non-profit board membership: American Brain Foundation, American Migraine Foundation, ONE Neurology, Precon Health Foundation, International Headache Society Global Patient Advocacy Coalition, Atria Health Collaborative, Domestic Violence HOPE Foundation/Panfla, CSF Leak Foundation. Research Support: Department of Defense, National Institutes of Health, Henry Jackson Foundation, Sperling Foundation, American Migraine Foundation, and Patient Centered Outcomes Research Institute (PCORI); stock options/shareholder/patents/board of directors: Ctrl M (options), Aural analytics (options), ExSano (options), Palion (options), Healint (options), Theranica (options), Second Opinion/Mobile Health (options), Epien (options/board),

Nocira (options), Matterhorn (shares/board), Ontologics (shares/board), King-Devick Technologies (options/board), Precon Health (options/board), AYYA Biosciences (options), Axon Therapeutics (options/board), Cephalgia Group (options/board), and Atria Health (options/salary). Patent 17189376.1-1466vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis (No fee/compensation/royalty). RCC is a Senior Advisor to the NFL Head Neck & Spine Committee; Vice President, National Operating Committee on Standards for Athletic Equipment; and Chair, Scientific Advisory Committee, Co-Founder, and Medical Director, Concussion Legacy Foundation. He is a member of the Medical Science Committee for the National Collegiate Athletic Association Student-Athlete Concussion Injury Litigation, and he receives royalties for published books from Houghton Mifflin Harcourt. JLC has provided consultation to Acadia, Alkahest, Aribio, Avani, Axsome, Behren Therapeutics, Biogen, Cassava, Cerecin, Cerevel, Cortexyme, EIP Pharma, Eisai, GemVax, Genentech, Green Valley, Grifols, Janssen, Jazz, Karuna, Merck, Novo Nordisk, Otsuka, ReMYND, Resverlogix, Roche, Samumed, Samus, Signant Health, Sunovion, Suven, United Neuroscience, and Unlearn AI pharmaceutical and assessment companies. He owns the copyright of the Neuropsychiatric Inventory. EMR is a compensated scientific advisor for Alkahest, Alzheon, Aural Analytics, Denali, Green Valley, Retromer Therapeutics, and Vaxinity and a co-founder of ALZPath. RAS is a paid consultant to Biogen (Cambridge, MA, USA). He is a member of the Board of Directors of King-Devick Technologies, Inc. (Chicago, IL, USA), and he receives royalties for published neuropsychological tests from Psychological Assessment Resources, Inc. (Lutz, FL, USA). He is a member of the Medical Science Committee for the National Collegiate Athletic Association Student-Athlete Concussion Injury Litigation. The remaining authors have no conflicts of interest to disclose.

Author details

¹Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Robinson Building, Suite B7800, Boston, MA 02118, USA. ²Department of Neurology, NYU Grossman School of Medicine, New York, NY, USA. ³Department of Neuroscience, University of California, San Diego, CA, USA. ⁴Department of Psychiatry, University of California, San Diego, CA, USA. ⁵Department of Psychiatry and Psychology, Mayo Clinic School of Medicine, Mayo Clinic Arizona, Scottsdale, AZ, USA. ⁶Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA. ⁷Boston University Alzheimer's Disease Research Center, Boston University CTE Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA. ⁸Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. ⁹Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ, USA. ¹⁰Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA. ¹¹Department of Ophthalmology, NYU Grossman School of Medicine, New York, NY, USA. ¹²Department of Neurology, University of Washington, Seattle, WA, USA. ¹³Department of Environmental Health, Boston University School of Public Health, Boston, MA, USA. ¹⁴Framingham Heart Study, Framingham, MA, USA. ¹⁵Slope Epidemiology Center, Boston University, Boston, MA, USA. ¹⁶Department of Anatomy & Neurobiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA. ¹⁷Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA. ¹⁸Department of Clinical Research & Leadership, The George Washington University School of Medicine & Health Sciences, Washington, DC, USA. ¹⁹Biostatistics and Epidemiology Data Analytics Center (BEDAC), Boston University School of Public Health, Boston, MA, USA. ²⁰Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA. ²¹Banner Alzheimer's Institute, University of Arizona, Arizona State University, Translational Genomics Research Institute, and Arizona Alzheimer's Consortium, Phoenix, AZ, USA. ²²Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA. ²³VA Boston Healthcare System, Boston, MA, USA. ²⁴Department of Neurosurgery, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.

Received: 2 September 2022 Accepted: 16 December 2022
Published online: 03 January 2023

References

- Montenegro PH, Alosco ML, Martin BM, Daneshvar DH, Mez J, Chaisson CE, et al. Cumulative head impact exposure predicts later-life depression, apathy, executive dysfunction, and cognitive impairment in former high school and college football players. *J Neurotrauma*. 2017;34(2):328–40.
- Roberts AL, Pascual-Leone A, Speizer FE, Zafonte RD, Baggish AL, Taylor H Jr, et al. Exposure to American football and neuropsychiatric health in former national football league players: findings from the football players health study. *Am J Sports Med*. 2019;47(12):2871–80.
- Schaffert J, LoBue C, Fields L, Wilmoth K, Didehban N, Hart J Jr, et al. Neuropsychological functioning in ageing retired NFL players: a critical review. *Int Rev Psychiatry*. 2020;32(1):71–88.
- Wright MJ, Woo E, Birath JB, Siders CA, Kelly DF, Wang C, et al. An index predictive of cognitive outcome in retired professional American Football players with a history of sports concussion. *J Clin Exp Neuropsychol*. 2016;38(5):561–71.
- Mez J, Alosco ML, Daneshvar DH, Saltiel N, Baucom Z, Abdolmohammadi B, et al. Validity of the 2014 traumatic encephalopathy syndrome criteria for CTE pathology. *Alzheimers Dement*. 2021;17(10):1709–24.
- Brett BL, Nader AM, Kerr ZY, Chandran A, Walton SR, DeFreese JD, et al. Disparate associations of years of football participation and a metric of head impact exposure with neurobehavioral outcomes in former collegiate football players. *J Int Neuropsychol Soc*. 2022;28(1):22–34.
- Mez J, Daneshvar DH, Kiernan PT, Abdolmohammadi B, Alvarez VE, Huber BR, et al. Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football. *JAMA*. 2017;318(4):360–70.
- Bieniek KF, Blessing MM, Heckman MG, Diehl NN, Serie AM, Paolini MA 2nd, et al. Association between contact sports participation and chronic traumatic encephalopathy: a retrospective cohort study. *Brain Pathol*. 2020;30(1):63–74.
- Bieniek KF, Ross OA, Cormier KA, Walton RL, Soto-Ortolaza A, Johnston AE, et al. Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. *Acta Neuropathol*. 2015;130(6):877–89.
- Katz DI, Bernick C, Dodick DW, Mez J, Mariani ML, Adler CH, et al. National Institute of Neurological Disorders and Stroke consensus diagnostic criteria for traumatic encephalopathy syndrome. *Neurology*. 2021;96(18):848–63.
- Weintraub S, Wicklund AH, Salmon DP. The neuropsychological profile of Alzheimer disease. *Cold Spring Harb Perspect Med*. 2012;2(4):a006171.
- Wittenberg D, Possin KL, Rascovsky K, Rankin KP, Miller BL, Kramer JH. The early neuropsychological and behavioral characteristics of frontotemporal dementia. *Neuropsychol Rev*. 2008;18(1):91–102.
- Montenegro PH, Baugh CM, Daneshvar DH, Mez J, Budson AE, Au R, et al. Clinical subtypes of chronic traumatic encephalopathy: literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome. *Alzheimers Res Ther*. 2014;6(5):68.
- Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7(3):270–9.
- McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7(3):263–9.
- Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain*. 2011;134(Pt 9):2456–77.
- Association AP. Diagnostic and statistical manual of mental disorders. 5th ed; 2013.
- McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. *Neurology*. 2017;89(1):88–100.
- Vellas B, Bateman R, Blennow K, Frisoni G, Johnson K, Katz R, et al. Endpoints for pre-dementia AD trials: a report from the EU/US/CTAD Task Force. *J Prev Alzheimers Dis*. 2015;2(2):128–35.
- Alosco ML, Mariani ML, Adler CH, Balcer LJ, Bernick C, Au R, et al. Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project. *Alzheimers Res Ther*. 2021;13(1):136.

21. Tombaugh T. Test of Memory Malingering (TOMM). North Tonawanda: Multi-Health Systems; 1996.
22. Wilkinson GS, Robertson GJ. Wide range achievement test: psychological assessment resources; 2006.
23. Benedict RHB. Brief visuospatial memory test-revised. Lutz: Psychological Assessment Resources; 1997.
24. Stern RA, White T. Neuropsychological assessment battery. Lutz: Psychological Assessment Resources, Inc; 2003.
25. Tombaugh TN, Kozak J, Rees L. Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. *Arch Clin Neuropsychol*. 1999;14(2):167–77.
26. Golden CJ, Freshwater SM. Stroop color and word test. Torrance: Western Psychological Services (WPS); 2002.
27. Smith A. Symbol digit modalities test. Los Angeles: Western Psychological Services; 1973.
28. Woodard JL, Benedict RH, Roberts VJ, Goldstein FC, Kinner KM, Capruso DX, et al. Short-form alternatives to the Judgment of Line Orientation Test. *J Clin Exp Neuropsychol*. 1996;18(6):898–904.
29. Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, Wu J, et al. The National Alzheimer's Coordinating Center (NACC) database: the uniform data set. *Alzheimer Dis Assoc Disord*. 2007;21(3):249–58.
30. Weintraub S, Besser L, Dodge HH, Teylan M, Ferris S, Goldstein FC, et al. Version 3 of the Alzheimer Disease Centers' neuropsychological test battery in the Uniform Data Set (UDS). *Alzheimer Dis Assoc Disord*. 2018;32(1):10–7.
31. Oltra-Cucarella J, Sanchez-SanSegundo M, Rubio-Aparicio M, Arango-Lasprilla JC, Ferrer-Cascales R. The association between the number of neuropsychological measures and the base rate of low scores. *Assessment*. 2021;28(3):955–63.
32. Schroeder RW, Martin PK, Heinrichs RJ, Baade LE. Research methods in performance validity testing studies: criterion grouping approach impacts study outcomes. *Clin Neuropsychol*. 2019;33(3):466–77.
33. Sherman EMS, Slick DJ, Iverson GL. Multidimensional malingering criteria for neuropsychological assessment: a 20-year update of the Malingered Neuropsychological Dysfunction Criteria. *Arch Clin Neuropsychol*. 2020;35(6):735–64.
34. Alosco ML, Jarnagin J, Tripodis Y, Martin B, Chaisson C, Baugh CM, et al. Utility of providing a concussion definition in the assessment of concussion history in former NFL players. *Brain Inj*. 2017;31(8):1116–23.
35. Binder LM, Iverson GL, Brooks BL. To err is human: "abnormal" neuropsychological scores and variability are common in healthy adults. *Arch Clin Neuropsychol*. 2009;24(1):31–46.
36. Walton SR, Kerr ZY, Mannix R, Brett BL, Chandran A, DeFreese JD, et al. Subjective concerns regarding the effects of sport-related concussion on long-term brain health among former NFL players: an NFL-LONG Study. *Sports Med*. 2022;52(5):1189–1203.
37. Gavett BE, Poon SJ, Ozonoff A, Jefferson AL, Nair AK, Green RC, et al. Diagnostic utility of the NAB List Learning test in Alzheimer's disease and amnesic mild cognitive impairment. *J Int Neuropsychol Soc*. 2009;15(1):121–9.
38. Randolph C, Karantzoulis S, Guskiewicz K. Prevalence and characterization of mild cognitive impairment in retired national football league players. *J Int Neuropsychol Soc*. 2013;19(8):873–80.
39. Boone KB, Ponton MO, Gorsuch RL, Gonzalez JJ, Miller BL. Factor analysis of four measures of prefrontal lobe functioning. *Arch Clin Neuropsychol*. 1998;13(7):585–95.
40. Chaytor N, Schmitter-Edgecombe M, Burr R. Improving the ecological validity of executive functioning assessment. *Arch Clin Neuropsychol*. 2006;21(3):217–27.
41. Phelps A, Alosco ML, Baucum Z, Hartlage K, Palmisano JN, Weuve J, et al. Association of playing college American football with long-term health outcomes and mortality. *JAMA Netw Open*. 2022;5(4):e228775.
42. Manly JJ, Echemendia RJ. Race-specific norms: using the model of hypertension to understand issues of race, culture, and education in neuropsychology. *Arch Clin Neuropsychol*. 2007;22(3):319–25.
43. Possin KL, Tsoy E, Windon CC. Perils of race-based norms in cognitive testing: the case of former NFL players. *JAMA Neurol*. 2021;78(4):377–8.
44. Crawford JR, Garthwaite PH, Gault CB. Estimating the percentage of the population with abnormally low scores (or abnormally large score differences) on standardized neuropsychological test batteries: a generic method with applications. *Neuropsychology*. 2007;21(4):419–30.
45. Bondi MW, Edmonds EC, Jak AJ, Clark LR, Delano-Wood L, McDonald CR, et al. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. *J Alzheimers Dis*. 2014;42(1):275–89.
46. Brooks BL, Iverson GL, White T. Substantial risk of "Accidental MCI" in healthy older adults: base rates of low memory scores in neuropsychological assessment. *J Int Neuropsychol Soc*. 2007;13(3):490–500.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

